Rosiglitazone inhibits α4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor γ-independent signals

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 110-118

  Sun, Xiaojuan ^a   Ritzenthaler, Jeffrey D ^a   Zheng, Ying ^a,c   Roman, Jesse ^a,b   Han, ShouWei ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINE; NICOTINIC RECEPTOR ALPHA4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; PROTEIN P53; ROSIGLITAZONE; SMALL INTERFERING RNA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA4 SUBUNIT; NICOTINIC RECEPTOR;

ARTICLE; CANCER CELL; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; DRUG EFFECT; LUNG TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149492415     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0719     Document Type: Article

References (43)

1. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-37.
2. Li MD. The genetics of nicotine dependence. Curr Psychiatry Rep 2006;8:158-64.
3. Tsurutani J, Castillo SS, Brognard J, et al. Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis 2005;26:1182-95.
4. Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by Inducing fibronectin expression. Am J Respir Cell Mol Biol 2007;37:681-90.
5. Lam DC, Girard L, Ramirez R, et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007;67:4638-47.
6. Zhang Q, Tang X, Zhang ZF, Velikina R, Shi S, Le AD. Nicotine induces hypoxia-inducible factor-1α expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin Cancer Res 2007;13:4686-94.
7. Hruska M, Nishi R. Cell-autonomous inhibition of α7-containing nicotinic acetylcholine receptors prevents death of parasympathetic neurons during development. J Neurosci 2007;27:11501-9.
8. Thompson SA, Smith O, Linn DM, Linn CL. Acetylcholine neuroprotection against glutamate-induced excitotoxicity in adult pig retinal ganglion cells is partially mediated through α4 nAChRs. Exp Eye Res 2006;83:1135-45.
9. Tan NS, Michalik L, Desvergne B, Wahli W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol 2005;93:99-105.
10. Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-γ is a new therapeutic target in sepsis and inflammation. Shock 2005;23:393-9.
11. Han S, Roman J. Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics? Anticancer Drugs 2007;18:237-44.
12. 2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein δ. J Biol Chem 2005;280:33240-9.
13. Han SW, Lei ZM, Rao CV. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 1996;137:1791-7.
14. Dasgupta P, Rastogi S, Pillai S, et al. Nicotine induces cell proliferation by β-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116:2208-17.
15. Grozio A, Catassi A, Cavalieri Z, Paleari L, Cesario A, Russo P. Nicotine, lung and cancer. Anticancer Agents Med Chem 2007;7:461-6.
16. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006;5:2324-8.
17. Yano M, Matsumura T, Senokuchi T, et al. Statins activate peroxisome proliferator-activated receptor g through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007;100:1442-51.
18. Li M, Lee TW, Mok TS, Warner TD, Yim AP, Chen GG. Activation of peroxisome proliferator-activated receptor-γ by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 2005;96:760-74.
19. Han S, Zheng Y, Roman J. Rosiglitazone, an agonist of PPARγ, inhibits non-small cell carcinoma cell proliferation in part through activation of tumor sclerosis complex-2. PPAR Res 2007;2007:29632.
20. 2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 2007;18:65-78.
21. Skok MV, Kalashnik EN, Koval LN, et al. Functional nicotinic acetylcholine receptors are expressed in B lymphocyte-derived cell lines. Mol Pharmacol 2003;64:885-9.
22. 2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci 1999;19:4804-14.
23. 2 neuronal nicotinic receptors depend on subunit ratio. J Biol Chem 2004;279:38007-15.
24. Guo J, Chu M, Abbeyquaye T, Chen CY. Persistent nicotine treatment potentiates amplification of the dihydrofolate reductase gene in rat lung epithelial cells as a consequence of Ras activation. J Biol Chem 2005;280:30422-31.
25. 2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007;71:1715-20.
26. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol Cancer Ther 2006;5:430-7.
27. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol 1997;15:193-222.
28. Su X, Lee JW, Matthay ZA, et al. Activation of the α7 nAChR reduces acid-induced acute lung injury in mice and rats. Am J Respir Cell Mol Biol 2007;37:186-92.
29. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br J Pharmacol 2004;143:933-7.
30. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U. Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 2005;213:157-68.
31. Ferruzzi P, Ceni E, Tarocchi M, et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005;90:1332-9.
32. Talbert DR, Allred CD, Zaytseva YY, Kilgore MW. Transactivation of ERα by rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat 2008;108:23-33.
33. Lennon AM, Ramauge M, Dessouroux A, Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Δ(12-14)- prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor γ-independent mechanisms involving reactive oxygenated species. J Biol Chem 2002;277:29681-5.
34. Lewthwaite JC, Bastow ER, Lamb KJ, Blenis J, Wheeler-Jones CP, Pitsillides AA. A specific mechanomodulatory role for p38 MAPK in embryonic joint articular surface cell MEK-ERK pathway regulation. J Biol Chem 2006;281:11011-8.
35. Shimo T, Matsumura S, Ibaragi S, et al. Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells. J Cell Commun Signal 2007;1:103-11.
36. Goetze S, Kintscher U, Kim S, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. J Cardiovasc Pharmacol 2001;38:909-21.
37. Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int 2004;65:1664-75.
38. Yang YC, Tsao YP, Ho TC, Choung IP. Peroxisome proliferator-activated receptor-γ agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 2007;17:418-25.
39. Bonofiglio D, Aquila S, Catalano S, et al. Peroxisome proliferator-activated receptor-γ activates p53 gene promoter binding to the nuclear factor-κB sequence in human MCF7 breast cancer cells. Mol Endocrinol 2006;20:3083-92.
40. Huang CL, Yokomise H, Miyatake A. Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers. Future Oncol 2007;3:83-93.
41. Li Y, Lin B, Agadir A, et al. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol 1998;18:4719-31.
42. Li L, Guo L, Tao Y, et al. Latent membrane protein 1 of Epstein-Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Lett 2007;255:219-31.
43. Lee YJ, Kuo HC, Chu CY, Wang CJ, Lin WC, Tseng TH. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. Biochem Pharmacol 2003;66:2281-9.